148 related articles for article (PubMed ID: 18511926)
1. Bendamustine.
Keating MJ; Bach C; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2008 Jun; 7(6):473-4. PubMed ID: 18511926
[No Abstract] [Full Text] [Related]
2. Bendamustine for treatment of chronic lymphocytic leukemia.
Chang JE; Kahl BS
Expert Opin Pharmacother; 2012 Jul; 13(10):1495-505. PubMed ID: 22663160
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine in CLL: How quickly will today's consensus become tomorrow's memory?
Cheson BD
Leuk Res; 2014 Nov; 38(11):1267-8. PubMed ID: 25260826
[No Abstract] [Full Text] [Related]
4. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
[No Abstract] [Full Text] [Related]
5. Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients.
Montillo M; Tedeschi A; Gaidano G; Coscia M; Petrizzi VB; Orlandi E; Cascavilla N; Ghia P; Motta M; Gallamini A; Frustaci AM; Rossi D; De Paoli L; Nichelatti M; Morra E; Massaia M
Haematologica; 2014 Sep; 99(9):e159-61. PubMed ID: 24972768
[No Abstract] [Full Text] [Related]
6. Bendamustine-induced "flagellate dermatitis".
Mahmoud BH; Eide MJ
Dermatol Online J; 2012 Nov; 18(11):12. PubMed ID: 23217953
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
Glode AE; Jarkowski A
Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
[TBL] [Abstract][Full Text] [Related]
8. The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis.
Nordstrom BL; Knopf KB; Teltsch DY; Engle R; Beygi H; Sterchele JA
Leuk Lymphoma; 2014 Jun; 55(6):1266-73. PubMed ID: 23987821
[TBL] [Abstract][Full Text] [Related]
9. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.
Goldschmidt N; Gural A; Ben-Yehuda D; Gatt ME
Cancer Chemother Pharmacol; 2013 Sep; 72(3):709-13. PubMed ID: 23907444
[TBL] [Abstract][Full Text] [Related]
10. Huge kidneys in a patient with chronic lymphocytic leukaemia.
Esposito P; Libetta C; Rampino T; Gregorini M; Margiotta E; Dal Canton A
Br J Haematol; 2015 Feb; 168(4):470. PubMed ID: 25384540
[No Abstract] [Full Text] [Related]
11. Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
García-Muñoz R; García DK; Roldán-Galiacho V; Merchante-Andreu M; Campeny-Najara A; Rabasa P
Ann Hematol; 2014 Apr; 93(4):699-702. PubMed ID: 23907409
[No Abstract] [Full Text] [Related]
12. Treanda approved for chronic lymphocytic leukemia.
Traynor K
Am J Health Syst Pharm; 2008 May; 65(9):793. PubMed ID: 18436722
[No Abstract] [Full Text] [Related]
13. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.
Kath R; Blumenstengel K; Fricke HJ; Höffken K
J Cancer Res Clin Oncol; 2001 Jan; 127(1):48-54. PubMed ID: 11206271
[TBL] [Abstract][Full Text] [Related]
15. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.
Cuneo A; Marchetti M; Barosi G; Billio A; Brugiatelli M; Ciolli S; Laurenti L; Mauro FR; Molica S; Montillo M; Zinzani P; Tura S
Leuk Res; 2014 Nov; 38(11):1269-77. PubMed ID: 25063524
[TBL] [Abstract][Full Text] [Related]
16. Bendamustine can severely impair T-cell immunity against cytomegalovirus.
Hosoda T; Yokoyama A; Yoneda M; Yamamoto R; Ohashi K; Kagoo T; Ueno H; Boku S; Yano T
Leuk Lymphoma; 2013 Jun; 54(6):1327-8. PubMed ID: 23072371
[No Abstract] [Full Text] [Related]
17. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.
Zaja F; Mian M; Volpetti S; Visco C; Sissa C; Nichele I; Castelli M; Ambrosetti A; Puglisi S; Fanin R; Cortelazzo S; Pizzolo G; Trentin L; Rodeghiero F; Paolini R; Vivaldi P; Sancetta R; Isola M; Semenzato G
Am J Hematol; 2013 Nov; 88(11):955-60. PubMed ID: 23861234
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Vidal L; Gafter-Gvili A; Gurion R; Raanani P; Dreyling M; Shpilberg O
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD009045. PubMed ID: 22972131
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma.
Hoy SM
Drugs; 2012 Oct; 72(14):1929-50. PubMed ID: 22950536
[TBL] [Abstract][Full Text] [Related]
20. [Toxicodermia by bendamustine: development of a desensization protocol].
Sangrador Pelluz C; Luis Hidalgo MM; Martínez García M; Pérez-Serrano Lainosa MD; Soler Company E
Farm Hosp; 2013; 37(5):421-3. PubMed ID: 24128107
[No Abstract] [Full Text] [Related]
[Next] [New Search]
